Agenda for September 5 TC meeting

Transparency Commission

3 September 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of the following technologies:

  • Pembrolizumab (Keytruda)
  • Exenatide (Bydureon)
  • Cariprazine hydrochloride (Reagila)
  • Bictegravir sodium with emtricitabine and tenofovir alafenamide fumarate (Biktarvy)
  • Velmanase alfa (Lamzede)
  • Insulin degludec (Tresiba)

Read TC Agenda [French] 

Michael Wonder

Posted by:

Michael Wonder